TY - JOUR
T1 - Design, synthesis, and evaluation of novel 6-chloro-/fluorochromone derivatives as potential topoisomerase inhibitor anticancer agents
AU - Ishar, M.P.S.
AU - Singh, G.
AU - Singh, S.
AU - Sreenivasan, K.K.
N1 - Cited By :74
Export Date: 10 November 2017
CODEN: BMCLE
Correspondence Address: Ishar, M.P.S.; Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar 143 005, Punjab, India; email: [email protected]
Chemicals/CAS: Antineoplastic Agents; Chromones; DNA Topoisomerases, EC 5.99.1.-; Enzyme Inhibitors
References: Champaux, J., (1990) DNA Topology and Its Biological Effects, p. 217. , J.C. Wang N.R. Cozarelli Cold Spring Harbor Laboratory Cold Spring Harbor, NY; Hsieh, T.-S., (1990) DNA Topology and Its Biological Effects, p. 243. , J.C. Wang N.R. Cozarelli Cold Spring Harbor Laboratory Cold Spring Harbor, NY; Caserta, M., Amadei, A., Camilloni, G., Di Mauro, E., (1990) Biochemistry, 29, p. 8152; Harrnon, F.G., Digate, R.J., Kowalczykowski, S.C., (1999) Mol. Cell, 3, p. 611; Nagarajan, M., Morrell, A., Fort, B.C., Meckley, M.R., Antony, S., Kholhagen, G., Pommier, Y., Cushman, M., (2004) J. Med. Chem., 47, p. 5651; Pommier, Y., Tanizawa, A., (1993) Cancer Chemotherapy, p. 214. , J. Hickman T. Tritton Blackwell Scientific Publications Oxford; Chen, A.U., Liu, L.F., (1994) Annu. Rev. Pharmacol. Toxicol., 94, p. 194; Zewail-Foote, M., Hurley, L., (1999) Anti-Cancer Drug Des., 14, p. 1; Levine, C., Hiasa, H., Marians, K.J., (1998) Biochim. Biophys. Acta, 1400, p. 29; Potmesil, M., Kohn, K.K., (1991) Topoisomerases in Cancer, , Oxford University Press: New York, Chapter 2; Osheroff, N., (1989) Pharmacol. Ther., 41, p. 223; Spicer, J., Finlay, G., Baguley, B., Velea, L., Graves, D., Denny, W., (1999) Anti-Cancer Drug Des., 14, p. 37; Gootz, T.D., Birghty, K.E., (1998) The Quinolones, p. 29. , V.T. Andriole 2nd ed. Academic Press San Diego; Hooper, D.C., (2001) Clin. Infect. Dis., 32, p. 9; Fan, J.-Y., Sun, D., Yu, H., Kerwin, S.M., Hurley, L.H., (1995) J. Med. Chem., 38, p. 408; Laco, G.S., Du, W., Kohlhagen, G., Sayer, J.M., Jerina, D.M., Burke, T.G., Curran, D.P., Pommier, Y., (2004) Biorg. Med. Chem., 12, p. 5225; Cianchetta, G., Mannhold, R., Cruciani, G., Baroni, M., Cecchetti, V., (2004) J. Med. Chem., 47, p. 3193; Hsiang, Y.-H., Hertzberg, R., Hecht, S., Liu, L.F., (1985) J. Biol. Chem., 260, p. 14873; Mhaske, S.B., Argade, N.P., (2004) J. Org. Chem., 69, p. 4563; Nagarajan, M., Xiao, X., Antony, S., Kohlhagen, G., Pommier, Y., Cushman, M., (2003) J. Med. Chem., 46, p. 5712; Wall, M.E., (1998) Med. Res. Rev., 18, p. 299; Cragg, G.M., Newman, D.J., (2004) J. Nat. Prod., 67, p. 232; Osheroff, N., Zechiedrich, E.L., Gale, K.C., (1991) BioEssays, 13, p. 269; Rahier, N.J., Eisenhauer, B.M., Gao, R., Jones, S.H., Shannon, R.G., Hecht, S.M., (2004) Org. Lett., 6, p. 321; Arimondo, P., Boukarim, C., Bailly, C., Dauzonne, D., Monneret, C., (2000) Anti-Cancer Drug Des., 15, p. 413; Xiao, Z., Vance, J.R., Bastow, K.F., Brossi, A., Wang, H.-K., Lee, K.-H., (2004) Bioorg. Med. Chem. Lett., 12, p. 3363; Cassady, J.M., Baird, W.M., Chang, C.J., (1990) J. Nat. Prod., 53, p. 23; Kupchan, S.M., Streelman, D.R., Sneden, A.T., (1980) J. Nat. Prod., 43, p. 296; Kim, M.Y., Na, Y., Vankayalapati, H., Gleason-Guzman, M., (2003) J. Med. Chem., 46, p. 2958; Kwok, Y., Sun, D., Clement, J., Hurley, L., (1999) Anti-Cancer Drug Des., 14, p. 443; Domagala, J.M., (1994) J. Antimicrob. Chemother., 33, p. 685; Bryskier, A., Chantot, J.-F., (1995) Drugs, 49 (SUPPL. 2), p. 16; Gootz, T.D., Brighty, K.E., (1996) Med. Res. Rev., 16, p. 433; Xia, Y., Yang, Z.-Y., Xia, P., Hackl, T., Hamel, E., Mauger, A., Wu, J.-H., Lee, K.-H., (2001) J. Med. Chem., 44, p. 3932; Ishar, M.P.S., Kumar, K., Singh, R., (1998) Tetrahedron Lett., 39, p. 6547; Singh, G., Singh, R., Girdhar, N.K., Ishar, M.P.S., (2002) Tetraherdon, 58, p. 2471; Singh, G., Singh, L., Ishar, M.P.S., (2002) Tetraherdon, 58, p. 7883; note; note; Gupta, M., Mazumder, U.K., Kumar, R.S., Kumar, T.S., (2004) Acta Pharmacol. Sin., 25, p. 1070; Bhattacharyya, A., Choudhuri, T., Pal, S., Chattopadhyay, S., Datta, G.K., Sa, G., Das, T., (2003) Carcinogensis, 24, p. 75; note; note; Lowry, O.H., Roesebrough, N.J., Farr, A.L., Randall, R.J., (1951) J. Biol. Chem., 193, p. 265; Moron, M.S., Depierre, J.W., Mannervik, B., (1979) Biochim. Biophys. Acta, 5820, p. 62; note; Yagi, K., (1991) Chem. Phys. Lipids, 45, p. 337; Sinclair, A.J., Barnett, A.H., Lunie, J., (1990) Br. J. Hosp. Med., 43, p. 334
PY - 2006
Y1 - 2006
N2 - 6-Chloro-2-pyrrolidino-/morpholino-/piperidino-/N-methylpiperazino-3- formyl-chromones (13-16) and 6-fluoro-2,7-di-morpholino-/piperidino-/N- methylpiperazino-3-formylchromones (17-19) have been synthesized as potential topoisomerase inhibitor anticancer agents, and evaluated, in vitro, against Ehrlich ascites carcinoma (EAC) cells, and also in vivo on EAC bearing mice. The compounds displayed promising anticancer activity under these test systems and shall serve as useful 'leads' for further design. © 2005 Elsevier Ltd. All rights reserved.
AB - 6-Chloro-2-pyrrolidino-/morpholino-/piperidino-/N-methylpiperazino-3- formyl-chromones (13-16) and 6-fluoro-2,7-di-morpholino-/piperidino-/N- methylpiperazino-3-formylchromones (17-19) have been synthesized as potential topoisomerase inhibitor anticancer agents, and evaluated, in vitro, against Ehrlich ascites carcinoma (EAC) cells, and also in vivo on EAC bearing mice. The compounds displayed promising anticancer activity under these test systems and shall serve as useful 'leads' for further design. © 2005 Elsevier Ltd. All rights reserved.
U2 - 10.1016/j.bmcl.2005.11.044
DO - 10.1016/j.bmcl.2005.11.044
M3 - Article
SN - 0960-894X
VL - 16
SP - 1366
EP - 1370
JO - Bioorganic and Medicinal Chemistry Letters
JF - Bioorganic and Medicinal Chemistry Letters
IS - 5
ER -